September 26, 2016 5:18 AM ET


Company Overview of AnaptysBio, Inc.

Company Overview

AnaptysBio, Inc., an antibody development company, engages in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology in the Unites states. It is developing ANB020, a pro-inflammatory cytokine antibody that inhibits the activity of interleukin-33; and ANB019, an antibody that inhibits the function of the interleukin-36-receptor. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is based in San Diego, California.

10421 Pacific Center Court

Suite 200

San Diego, CA 92121

United States

Founded in 2005

50 Employees





Key Executives for AnaptysBio, Inc.

Chief Executive Officer, President and Director
Age: 40
Age: 53
Chief Financial Officer
Age: 50
Head of Project Management
Chief Development Officer
Age: 59
Compensation as of Fiscal Year 2016.

AnaptysBio, Inc. Key Developments

AnaptysBio, Inc. Presents at 2016 Credit Suisse Antibody Day, Sep-07-2016

AnaptysBio, Inc. Presents at 2016 Credit Suisse Antibody Day, Sep-07-2016. Venue: Credit Suisse Offices, One Madison Avenue at 24th Street, 12th Floor, New York, New York, United States. Presentation Date & Speakers: Sep-07-2016, Hamza Suria, Chief Executive Officer, President and Director, Marco Londei, Chief Development Officer.

AnaptysBio, Inc. Presents at Wells Fargo Securities 2016 Healthcare Conference, Sep-07-2016

AnaptysBio, Inc. Presents at Wells Fargo Securities 2016 Healthcare Conference, Sep-07-2016 . Venue: The Westin Boston Waterfront Hotel, Boston, Massachusetts, United States.

AnaptysBio, Inc. Initiates Multiple Ascending Dose Cohorts in ANB020 Phase 1 Clinical Trial

AnaptysBio, Inc. announced the initiation of multiple ascending dose cohorts in an on-going double-blind, placebo-controlled healthy volunteer Phase 1 study of its proprietary anti-interleukin-33 antibody (ANB020). During an earlier segment of the aforementioned Phase 1 study, AnaptysBio conducted safety, tolerability, pharmacokinetic and pharmacodynamic assessment of ANB020 in healthy volunteer cohorts administered with single doses of the antibody. Data generated from single dose cohorts was reviewed by regulatory authorities in Australia prior to the initiation of multiple ascending dose testing. ANB020 is a potent inhibitor of interleukin-33 (IL-33) developed by AnaptysBio using its proprietary SHM-XEL antibody discovery platform. IL-33 is a pro-inflammatory cytokine that multiple studies have indicated is a central mediator of atopic diseases, including atopic dermatitis, food allergies and asthma. Since ANB020 acts upstream of IL-4, IL-5 and IL-13, AnaptysBio believes ANB020's IL-33 inhibitory mechanism has potential advantages in human therapy over agents that block only a subset of the cytokines responsible for atopic diseases. In addition, published human genetic analyses have linked down-modulation of IL-33 signaling with protection from asthma. AnaptysBio plans to conduct future clinical development of ANB020 in patients with atopic dermatitis, peanut allergy and asthma.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact AnaptysBio, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at